Pharmacogenomics of Antiplatelet Response
概览
- 阶段
- 4 期
- 干预措施
- Aspirin
- 疾病 / 适应症
- Atherosclerosis
- 发起方
- Johns Hopkins University
- 入组人数
- 34
- 试验地点
- 1
- 主要终点
- Differential Gene Expression
- 状态
- 已完成
- 最后更新
- 9年前
概览
简要总结
This clinical trial will examine with effect of 2-week aspirin therapy on platelet gene expression in persons at high-risk of developing heart attacks due to family history of early-onset coronary artery disease
详细描述
In this clinical trials we will select individuals from GeneSTAR cohort based o their platelet function. Equal number of individuals will be selected from each race and gender and from low or high platelet aggregation. We will have baseline platelet functions performed and baseline platelet gene expression examined. Participants will be given 2-week supply of aspirin(81 mg/daily) and will be examined at the end of 2-weeks with platelet aggregation studies and a repeat platelet gene-expression (using RNA-seq). The ultimate goal is to examine platelet gene expression differences due to aspirin and across different gender, race, platelet-aggregation groups.
研究者
Rehan Qayyum
Assistant Professor
Johns Hopkins University
入排标准
入选标准
- •45-75 years
- •GeneSTAR participant
- •No personal History of Coronary Artery Disease
- •Women who are post-menopausal
- •Women who are using a reliable method of contraception, such as history of tubal ligation, IUD or taking OCP
排除标准
- •Taking aspirin prescribed by physician
- •weight \< 60 kg
- •History of recent or current bleeding
- •allergy to aspirin or history of adverse events to aspirin
- •serious comorbid conditions (such as AIDS, active cancer)
- •high blood pressure (\>160/95)
- •History of gastrointestinal ulcer/bleeding
- •Mental incompetence to make decision to participate.
研究组 & 干预措施
Aspirin
干预措施: Aspirin
结局指标
主要结局
Differential Gene Expression
时间窗: 2-weeks
Differences in platelet transcriptome before and after 2-week aspirin therapy The expression levels of genes before aspirin therapy was compared with the expression level of the genes after aspirin therapy. The expression levels were measured using the FPKM unit (Fragments Per Kilobase of transcript per Million mapped reads). The gene with the highest difference (pre vs. post) in FPKM is being reported with name in the units area and the actual difference in the number area